Australia's Sexual Health Landscape in 2026: What the Numbers Don't Say Loudly Enough

Australia has a habit of measuring its way to optimism. The HIV care continuum numbers look good on paper, with 92% of people living with HIV diagnosed, 97% of those on treatment, and 98% of those virally suppressed [1]. Read those figures alongside a 42% collapse in PrEP dispensing, a mpox resurgence that infected almost exclusively men, and congenital syphilis deaths in Western Australia, and a different picture emerges.

The UNAIDS 95-95-95 framework measures cascade performance among people already engaged with health services. The 8% of Australians living with HIV who remain undiagnosed are not in the cascade. They are concentrated in people born overseas, heterosexual men, and Aboriginal and Torres Strait Islander peoples, none of whom feature prominently in the community-based HIV prevention infrastructure built around inner-urban GBMSM communities [2].

A national shortage of tenofovir/emtricitabine products in 2023-24 caused PrEP dispensing to fall 42% across PBS-listed products. A Section 19A regulatory approval in October 2024 helped, but dispensing had not recovered to pre-shortage levels by year's end [3]. The 2026-27 Federal Budget allocates $40.5 million for HIV treatment and prevention, targeted at people with HIV ineligible for Medicare [4]. That funding addresses one cohort, whereas it does not address the supply chain design that failed in 2023-24, or the prevention gap among populations the existing infrastructure does not reach.

Australia's low mpox case numbers in 2022 were read as a success. They were also the reason vaccine coverage among GBMSM sat at approximately 50% nationally when a significant resurgence occurred in 2024, with 99% of cases in males [5]. Low case numbers meant low infection-induced immunity, and incomplete vaccination meant insufficient population-level protection entering 2024.

The TraX study found that most unvaccinated GBMSM underestimated their personal risk, encountered access barriers, or lacked sufficient vaccine knowledge to prompt uptake. Vaccine effectiveness against symptomatic mpox was estimated at 68.2% in comparable outbreak settings [6]. The barrier was reach, not the vaccine.

Congenital syphilis requires only antenatal screening and timely treatment of a known bacterial infection to prevent. In Western Australia between 2018 and 2023, 18 confirmed cases produced a 35% case fatality rate, including five stillbirths and one perinatal death [7]. The 2020 global congenital syphilis rate of 425 cases per 100,000 livebirths was more than eight times the WHO elimination target of 50 per 100,000, with resurgence documented across multiple high-income countries [8].

The federal allocation of $1.1 million for BBV and STI programs in the Torres Strait in 2026-27 reflects geographic risk concentration [4]. It does not address the antenatal care access gaps in remote and regional settings where syphilis transmission chains are established long before diagnosis occurs.

Australia's cervical cancer elimination trajectory is substantive, and the 2026-27 budget's $9 million for expanded screening builds on a functioning program [4]. A 2026 study of Aboriginal and Torres Strait Islander women found that only 55% of those who used HPV self-collection felt they had enough information to choose between collection methods, and more than half of recently screened participants had never been offered self-collection at all [9]. Self-collection was introduced to reduce barriers for under-screened populations. Inconsistent implementation means the equity benefit accrues mainly to populations already participating in screening.

Each condition described above disproportionately burdens populations with the least frequent contact with clinical services. Australia's sexual health investment has followed clinical infrastructure, prioritising treatment, testing, and surveillance, while the people least reached by that infrastructure continue to face barriers of geography, language, stigma, and a prevention system that assumes health system engagement as a precondition for health information. The result is a system that performs well for those already engaged with care but less effectively for those outside it.

Across HIV, mpox, syphilis and cervical screening, the evidence points to the same conclusion: improving outcomes depends not only on effective clinical interventions, but on reaching the people who are least likely to access them. Peer navigation, culturally competent outreach, and sustained community-facing communication were identified as essential to closing remaining HIV gaps [2], and the evidence supporting these approaches extends across sexual health more broadly. The next phase of investment can build on Australia's progress by extending effective care and prevention to communities that remain underserved.